CYP Shares Cynata Therapeutics Limited
ASX · ASXLast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Regenerative medicine platform has multiple clinical readouts that could materially improve investor visibility.
Signal breakdown
- ▸Two major clinical trial readouts expected in the June quarter.
- ▾Below 50-day MA (-0.16%)
- ▾Near 52-week low (0.4% of range)
Is CYP a buy right now?
Trend: CYP is trading above the 50-day average (+10.00%), RSI 41 — neutral momentum, with a 3-month return of -8.33%.
Valuation & quality: Cynata Therapeutics Limited trades on forward P/E -0.2; fundamentals show net margin 0.0%, return on equity -340.8%.
Our screen: WATCH (score 0) — Regenerative medicine platform has multiple clinical readouts that could materially improve investor visibility.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -16.20% | +3.20% | -12.50% | -96.40% | +0.00% | +0.00% | +0.00% | +0.00% |
Fundamentals
Technical signals
About Cynata Therapeutics Limited
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of a proprietary induced pluripotent stem cell (iPSC)-based platform technology under the Cymerus name in Australia.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.